City of Hope
1500 E Duarte Rd
Duarte
California
91010
United States
Tel: 800-826-4673
Website: https://www.cityofhope.org/careers
About City of Hope
City of Hope, an innovative biomedical research, treatment and educational institution with over 5,000 employees, is dedicated to the prevention and cure of cancer and other life-threatening diseases and guided by a compassionate, patient-centered philosophy.
Founded in 1913 and headquartered in Duarte, California, City of Hope is a remarkable non-profit institution, where compassion and advanced care go hand-in-hand with excellence in clinical and scientific research. City of Hope is a National Cancer Institute designated Comprehensive Cancer Center and a founding member of the National Comprehensive Cancer Network, an alliance of the nation’s 20 leading cancer centers that develops and institutes standards of care for cancer treatment.
Individually we are many things. Together, we are hope.
128 articles about City of Hope
-
This week's Movers & Shakers includes a number of chief business officers and business development leaders alongside those tapped for scientific roles.
-
Philip A. Okala Joins City of Hope as System President
6/14/2022
City of Hope, one of the largest cancer research and treatment organizations in the United States, announced that Philip Okala, chief operating officer at the University of Pennsylvania Health System, will join the organization as system president.
-
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
-
Eureka Therapeutics and City of Hope Treat First Patient with GPC3 Targeting ARTEMIS® T Cells (ECT204) for Advanced Liver Cancer
5/31/2022
Eureka Therapeutics and City of Hope Treat First Patient with GPC3 Targeting ARTEMIS ® T Cells (ECT204) for Advanced Liver Cancer.
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
City of Hope Doctors Present Novel Treatments for Bladder, Blood and Other Cancers at American Society of Clinical Oncology Annual Conference
5/27/2022
City of Hope, one of the largest cancer research and treatment organizations in the United States, announced it would present research on promising treatments for bladder and blood cancers, as well as studies on precision medicine and an experimental cancer vaccine, at the 2022 American Society of Clinical Oncology’s annual conference from June 3 to 7 in Chicago.
-
City of Hope to Expand Best-in-Class Supportive Care Program for Cancer Patients, Strengthen Advocacy for the Field With $10 Million Gift From The Sheri and Les Biller Family Foundation
5/24/2022
City of Hope, one of the largest cancer research and treatment organizations in the United States and a national leader in providing cancer patients with best-in-class, integrated supportive care programs, has received a $10 million gift from The Sheri and Les Biller Family Foundation.
-
Imugene and City of Hope announced that the first patient has begun treatment in a Phase I clinical trial, investigating the safety and efficacy of CF33-hNIS in adults with metastatic or advanced tumors.
-
Researchers continue to explore how to turn deadly venom into life-saving drugs. Several papers on the subject have recently been published and BioSpace is taking a look at them.
-
Curate Biosciences and City of Hope Evaluate Innovative Cell Separation for HIV CAR-T Cell Therapy Production
4/5/2022
Curate Biosciences announced the first outcome of its Technology Access Program, which is dedicated to converting research into real-world treatments and cures as rapidly as possible.
-
The man who many consider the father of synthetic insulin treatment for diabetes, as well as a founder of modern biotechnology- Dr. Arthur Riggs - died this week at the age of 82.
-
Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows It Produced Robust Antibodies and T Cells Against SARS-CoV-2
3/10/2022
A COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to GeoVax Labs Inc., produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in a Phase 1 clinical trial led by John Zaia, M.D., Aaron D. Miller and Edith Miller Chair for Gene Therapy, according to a study published in The Lancet Microbe.
-
Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles
3/8/2022
Australian clinical-stage drug development company Noxopharm has announced its Phase 1 CEP-2 sarcoma trial is underway with a first patient enrolled and dosed at City of Hope in Los Angeles, California.
-
City of Hope Researcher Advises Doctors Against Overreliance on a Popular Liquid Biopsy Used to Screen for Colorectal Cancer Recurrence
3/8/2022
Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, have data pointing to the limitations of Signatera, a popular liquid biopsy or blood draw test that is used to detect the recurrence of colorectal cancer in patients who have had their disease surgically removed.
-
City of Hope and Osel Announce Live Biotherapeutic Product CBM588 May Enhance Efficacy of Immunotherapy for Patients With Metastatic Kidney Cancer
2/28/2022
City of Hope and Osel Inc. announced Phase 1 trial data showing that use of the live biotherapeutic CBM588 plus immunotherapy medicine nivolumab/ipilimumab significantly improved progression-free survival in patients with metastatic kidney cancer when compared to use of nivolumab/ipilimumab alone.
-
City of Hope awarded $4.9 million from CIRM to train future leaders in stem cell biology and regenerative medicine
2/22/2022
City of Hope announced that its Department of Stem Cell Biology and Regenerative Medicine received a $4.9 million grant to train the next generation of scientific leaders in basic stem cell research and its translation into novel, lifesaving treatments.
-
Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium
2/15/2022
Mustang Bio, Inc. today announced that City of Hope Phase 1 clinical trial data on MB-105, a prostate stem cell antigen (“PSCA”) chimeric antigen receptor (“CAR”) T-cell therapy administered systemically to patients with PSCA-positive metastatic castration-resistant prostate cancer.
-
City of Hope Names New Chief Clinical Operating Officer
2/10/2022
City of Hope, one of the largest cancer research and treatment organizations in the United States, named Vince Jensen as its chief clinical operating officer.
-
City of Hope Completes Strategic Acquisition of Cancer Treatment Centers of America, Building a National, Integrated Cancer Research and Treatment System With a Singular Focus on Eradicating Cancer
2/2/2022
City of Hope has completed its previously announced acquisition of Cancer Treatment Centers of America (CTCA).
-
Ostentus Therapeutics, Inc., and City of Hope to Initiate Studies of Novel OST Natural Products for Treatment of Leukemia and Other Cancers
1/27/2022
Ostentus Therapeutics, Inc. , has entered into a Sponsored Research Agreement with City of Hope, a world-renowned cancer treatment and research organization and a National Cancer Institute-designated Comprehensive Cancer Center, to conduct preclinical research on OST compounds, which could be used as future therapies for leukemia and other cancers.